Compare Berkshire Hathaway Inc Class B (BRK.B) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Berkshire Hathaway Inc Class B vs Novartis AG — how do they compare? Berkshire Hathaway Inc Class B trades at $490, while Novartis AG trades at $151.3 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while Berkshire Hathaway Inc Class B pays none, and Novartis AG is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.
| BRK.B | NVS | |
|---|---|---|
Sector | Financials | Health |
52-Week High | $513.70 | $168.62 |
52-Week Low | $459.10 | $113.50 |
Market Cap | — | $288.65B |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BRK.B trades at $491.11, down 1.14% today, with a bullish technical signal driven by moving averages and an oversold 6-day RSI of 14.57. Support levels are firm near $483-$489, while resistance sits at $495-$501. Analyst consensus is positive with 57% buy ratings, though key financial ratios are unavailable in the provided data.
The outlook remains constructive given strong analyst support and technical oversold conditions, but risks include market volatility and reliance on Berkshire Hathaway's diverse portfolio performance. Upside depends on earnings momentum and macroeconomic stability.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Berkshire Hathaway Inc Class B
Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.
Read more on BRK.B →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
